title: Phosphorylation of extracellular signal-regulated kinase (ERK)-1/2 Is associated with the downregulation of peroxisome proliferator-activated receptor (PPAR)-γ during polymicrobial sepsis.
abstract: Peroxisome proliferator-activated receptor (PPAR)-γ is a ligand-activated transcription factor and regulates inflammation. Posttranslational modifications regulate the function of PPARγ, potentially affecting inflammation. PPARγ contains a mitogen-activated protein kinase (MAPK) site, and phosphorylation by extracellular signal-regulated kinase (ERK)-1/2 leads to inhibition of PPARγ. This study investigated the kinetics of PPARγ expression and activation in parenchymal and immune cells in sepsis using the MAPK/ERK kinase (MEK)-1 inhibitor, an upstream kinase of ERK1/2. Adult male Sprague Dawley rats were subjected to polymicrobial sepsis by cecal ligation and puncture. Rats received intraperitoneal injection of vehicle or the MEK1 inhibitor PD98059 (5 mg/kg) 30 min before cecal ligation and puncture. Rats were euthanized at 0, 1, 3, 6 and 18 h after cecal ligation and puncture. Control animals used were animals at time 0 h. Lung, plasma and peripheral blood mononuclear cells (PBMCs) were collected for biochemical assays. In vehicle-treated rats, polymicrobial sepsis resulted in significant lung injury. In the lung and PBMCs, nuclear levels of PPARγ were decreased and associated with an increase in phosphorylated PPARγ and phosphorylated ERK1/2 levels. Treatment with the MEK1 inhibitor increased the antiinflammatory plasma adipokine adiponectin, restored PPARγ expression in PBMCs and lung, and decreased lung injury. The inflammatory effects of sepsis cause changes in PPARγ expression and activation, in part, because of phosphorylation of PPARγ by ERK1/2. This phosphorylation can be reversed by ERK1/2 inhibition, thereby improving lung injury.
authors.affiliation: Division of Critical Care Medicine, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America. jennifer.kaplan@cchmc.org
authors.forename: Jennifer M
authors.initials: JM
authors.lastname: Kaplan
authors.forename: Paul W
authors.initials: PW
authors.lastname: Hake
authors.forename: Alvin
authors.initials: A
authors.lastname: Denenberg
authors.forename: Marchele
authors.initials: M
authors.lastname: Nowell
authors.forename: Giovanna
authors.initials: G
authors.lastname: Piraino
authors.forename: Basilia
authors.initials: B
authors.lastname: Zingarelli
mesh_terms: D052242:Adiponectin / Q000097:blood; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000493:pharmacokinetics; D015536:Down-Regulation; D008024:Ligands; D008168:Lung / Q000503:physiopathology; D008297:Male; D048052:Mitogen-Activated Protein Kinase 3 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D047495:PPAR gamma / Q000378:metabolism*; D010766:Phosphorylation; D051381:Rats; D017207:Rats, Sprague-Dawley; D018805:Sepsis / Q000378:metabolism / Q000382:microbiology*; D014157:Transcription Factors / Q000378:metabolism
chemical_list: D052242:Adiponectin; D000893:Anti-Inflammatory Agents; D008024:Ligands; D047495:PPAR gamma; D014157:Transcription Factors; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases
references.citation: J Biol Chem. 1997 Feb 21;272(8):5128-32
references.pmid: 9030579
references.citation: Intensive Care Med. 2010 Jan;36(1):123-30
references.pmid: 19760394
references.citation: Diabetologia. 1999 Jun;42(6):702-10
references.pmid: 10382590
references.citation: J Biol Chem. 1997 Apr 18;272(16):10811-6
references.pmid: 9099735
references.citation: J Biol Chem. 2000 Jun 16;275(24):18527-33
references.pmid: 10748014
references.citation: Science. 1996 Dec 20;274(5295):2100-3
references.pmid: 8953045
references.citation: Nature. 1998 Jan 1;391(6662):79-82
references.pmid: 9422508
references.citation: J Surg Res. 2006 Aug;134(2):348-53
references.pmid: 16488436
references.citation: Shock. 2005 Jul;24(1):59-65
references.pmid: 15988322
references.citation: Crit Care Clin. 2000 Apr;16(2):337-52, vii
references.pmid: 10768085
references.citation: Am J Physiol Regul Integr Comp Physiol. 2008 Jan;294(1):R84-92
references.pmid: 17989144
references.citation: Mol Cell Biol. 2007 Feb;27(3):803-17
references.pmid: 17101779
references.citation: BMC Pharmacol. 2004 Oct 18;4:23
references.pmid: 15491498
references.citation: Crit Care Med. 2004 Mar;32(3):826-31
references.pmid: 15090969
references.citation: Diabetes. 2002 Oct;51(10):2968-74
references.pmid: 12351435
references.citation: J Leukoc Biol. 2006 Jan;79(1):235-43
references.pmid: 16380602
references.citation: Diabetes. 2001 Sep;50(9):2094-9
references.pmid: 11522676
references.citation: Cancer Sci. 2010 Feb;101(2):396-402
references.pmid: 19917060
references.citation: Crit Care Med. 2005 Oct;33(10):2309-16
references.pmid: 16215386
references.citation: Biochem Biophys Res Commun. 1999 Oct 5;263(3):749-53
references.pmid: 10512751
references.citation: Blood. 2000 Sep 1;96(5):1723-32
references.pmid: 10961870
references.citation: Crit Care Med. 2007 May;35(5):1348-55
references.pmid: 17414724
references.citation: J Immunol. 2003 Dec 15;171(12):6827-37
references.pmid: 14662889
references.citation: Endocrinology. 1997 Jul;138(7):3073-6
references.pmid: 9202256
references.citation: Circulation. 1999 Dec 21-28;100(25):2473-6
references.pmid: 10604883
references.citation: J Biol Chem. 2000 Jan 14;275(2):1241-6
references.pmid: 10625669
references.citation: Endocrinology. 2002 Mar;143(3):998-1007
references.pmid: 11861525
references.citation: Diabetes. 2003 Jul;52(7):1655-63
references.pmid: 12829629
references.citation: J Cell Sci. 2004 Jul 15;117(Pt 16):3605-14
references.pmid: 15252128